TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04720014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP Group Intervention
Description: Nine 1.5 hour group sessions focusing on developing:~1. an understanding of stress physiology and the physiology of the relaxation response;~2. a regular practice of eliciting the relaxation response; and~3. cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice.
Study: NCT05814211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device - newly developed intermittent catheter
Description: Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device #1 - SpeediCath Eve
Description: During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device #2 - SpeediCath Compact Plus Female
Description: During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use.
Study: NCT01964937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123
Description: The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123
Description: The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123
Description: The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1
Description: The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1
Description: The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4
Description: The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4
Description: The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E®
Description: The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E®
Description: The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E®
Description: The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E®
Description: The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E®
Description: The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo vaccine
Description: The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo vaccine
Description: The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
Study: NCT05519371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
Study: NCT06233734

Intervention type: DEVICE
Intervention: The Lokomat (Hocoma, Zurich, Switzerland).
Description: The Lokomat is a device which can be used to implement robot-assisted gait training safely within disabled stroke populations. The robot-assisted gait training group will receive training via the Lokomat. Involvement in the study will not influence the duration or frequency of robot-assisted gait training sessions they receive. The amount of training they receive via the Lokomat will be determined (as per standard care) by the care team at the stroke ward.
Study: NCT05339477

Intervention type: OTHER
Intervention: Accelerometer measurement
Description: Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
Study: NCT05234320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CG-SpikeDown, intranasal formulation
Description: The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CG-SpikeDown, intranasal formulation
Description: The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-SpikeDown, intranasal formulation
Description: The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (Placebo)
Description: patients will receive active drug or placebo in addition to standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (Placebo)
Description: patients will receive active drug or placebo in addition to standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle (Placebo)
Description: patients will receive active drug or placebo in addition to standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of core (type of therapy is depend of decide of the site)
Description: patients will receive active drug or placebo in addition to standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of core (type of therapy is depend of decide of the site)
Description: patients will receive active drug or placebo in addition to standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of core (type of therapy is depend of decide of the site)
Description: patients will receive active drug or placebo in addition to standard of care
Study: NCT06178159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab Injection
Description: Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab Injection
Description: Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks
Study: NCT04758663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap/wake conditions on memory
Description: Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap/wake conditions on overnight physiology
Description: Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
Study: NCT05391711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Smart Relationships
Description: Mentors assigned to the intervention will receive the following trainings and support:~1. Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~2. Culturally Smart Relationships Training (live, virtual)~3. JEDI enhanced monthly supervision from case managers~4. Monthly emails with activity suggestions for mentors and youth
Study: NCT06264479

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Patients undergo a biopsy from a lesion, and give 40ml of blood
Study: NCT05547334

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inference Based Approach (IBA)
Description: The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
Study: NCT05828355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Care@Home Programme
Description: Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
Study: NCT05839145

Intervention type: OTHER
Group type: OTHER
Intervention: Strength force measurment
Description: The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)

Intervention type: OTHER
Group type: OTHER
Intervention: Strength force measurment
Description: The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)

Intervention type: OTHER
Group type: OTHER
Intervention: Time tests
Description: Lower and upper limb capacities of the patients will be measured during timed tests

Intervention type: OTHER
Group type: OTHER
Intervention: Time tests
Description: Lower and upper limb capacities of the patients will be measured during timed tests

Intervention type: OTHER
Group type: OTHER
Intervention: Motor scales
Description: Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)

Intervention type: OTHER
Group type: OTHER
Intervention: Motor scales
Description: Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometry
Description: Patients physical activity will be measured at home using accelerometer sensors

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometry
Description: Patients physical activity will be measured at home using accelerometer sensors

Intervention type: OTHER
Group type: OTHER
Intervention: MNR
Description: Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs

Intervention type: OTHER
Group type: OTHER
Intervention: MNR
Description: Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs

Intervention type: OTHER
Group type: OTHER
Intervention: Bio-impedance analysis
Description: The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)

Intervention type: OTHER
Group type: OTHER
Intervention: Bio-impedance analysis
Description: The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
Study: NCT06046716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful compassion based on behavioural change taxonomy experimental group
Description: Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful compassion based on behavioural change taxonomy experimental group
Description: Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
Study: NCT06552858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: 150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.
Study: NCT04347317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity IMT
Description: The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity IMT
Description: The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity.
Study: NCT04263480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib + Ibrutinib
Description: Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities
Study: NCT05140239

Intervention type: OTHER
Intervention: No Intervention
Description: Non Interventional
Study: NCT04843059

Intervention type: OTHER
Group type: OTHER
Intervention: The resident memory T-cell infiltrate in perilesional vitiligo skin
Description: The 3 groups will receive a combination of narrowband UVB (Nb-UVB) 3 times a week and oral mini pulses of systemic steroids (5 mg of d medrol 16mg twice a week) for 24 weeks.~Three visits will be done (inclusion, Week 12 and 24) A skin biopsy will be done on lesional and peri-lesional area at baseline. Another skin biopsy will be taken after 24 weeks but only in perilesional area. A blood sample for assessing the circulating memory T cells and for checking the tolerance will be performed at baseline, then at W12 and W24.
Study: NCT05392894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation
Description: Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.
Study: NCT04681196

Intervention type: OTHER
Intervention: patients shifted to nasal mask after persistent OSA with oronasal mask
Description: In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
Study: NCT05684146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emboliner Embolic Protection
Description: Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Cerebral Protection
Description: The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
Study: NCT05936658

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]Florastamin
Description: A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
Study: NCT05964686

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group (NaOCl/EDTA)
Description: conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dual laser group (Er,Cr:YSGG/Diode):
Description: Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
Study: NCT05964686

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined group (EDTA/Diode):
Description: 17% EDTA was used to remove smear layer followed by diode laser for disinfection
Study: NCT05001464

Intervention type: DEVICE
Intervention: reflectance pulse oximeter
Description: Wearing reflectance pulse oximeter at the same time on the night of PSG examination
Study: NCT06074302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA Redensity
Description: RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.